Δημοσίευση

Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.

ΤίτλοςLow dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.
Publication TypeJournal Article
Year of Publication2012
AuthorsTsirella, E., Mavrakanas T., Rager O., Tsartsalis S., Kallaras K., Kokkas B., & Mironidou-Tzouveleki M.
JournalJ Physiol Pharmacol
Volume63
Issue2
Pagination201-4
Date Published2012 Apr
ISSN1899-1505
Λέξεις κλειδιάAlkaline Phosphatase, Animals, Biological Markers, Bone Density, Bone Resorption, Calcium, Collagen Type I, Creatinine, Diabetes Mellitus, Experimental, Hypoglycemic Agents, Male, Osteocalcin, Osteogenesis, Peptides, Rats, Rats, Wistar, Thiazolidinediones
Abstract

Our study aims to investigate the effect of a low-dose pioglitazone regimen on bone mineral density and bone formation-resorption markers in control and diabetic rats. Wistar rats were divided into 4 groups: non-diabetic controls, control rats receiving pioglitazone (3 mg/kg), streptozocin-treated diabetic rats (50 mg/kg), diabetic rats treated with pioglitazone (3 mg/kg). The duration of the experiment was 8 weeks. Diabetes in our rats was associated with weight loss, increased urinary calcium excretion and reduced plasma osteocalcin levels. Diabetes mellitus did not affect bone mineral density. Pioglitazone administration had no impact on bone formation and resorption markers levels and did not modify bone mineral density in the four studied groups. Pioglitazone at the 3 mg/kg dose was not associated with significant skeletal complications in our experimental model.

Alternate JournalJ. Physiol. Pharmacol.
PubMed ID22653908

Επικοινωνία

Γραμματεία Τμήματος Ιατρικής T.K. 54124 Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα social networks.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.